Preservation of the ischemic canine myocardium: A comparison of hypothermia, lidoflazine, and ketanserin

Buckberg, 1981, Intraoperative myocardial protection, 231 Kirklin, 1979, Prevention of myocardial damage during cardiac operations, N Engl J Med, 301, 135, 10.1056/NEJM197907193010305 Buckley, 1977, Myocardial consequences of coronary artery bypass graft surgery. The paradox of necrosis in areas of revascularization, Circulation, 56, 906, 10.1161/01.CIR.56.6.906 Naylor, 1981, The role of calcium in the ischemic myocardium, Am J Pathol, 102, 262 Naylor, 1982, Protection of the myocardium against postischemic reperfusion damage. The combined effect of hypothermia and nifedipine, J Thorac Cardiovasc Surg, 84, 897, 10.1016/S0022-5223(19)38941-X Kates, 1983, Pretreatment with lidollazine, a calcium channel blocker. Useful adjunct to heterogeneous cold potassium cardioplegia, J Thorac Cardiovasc Surg, 85, 278, 10.1016/S0022-5223(19)38885-3 Flameng, 1981, Cardioprotective effects of lidollazine during 1-hour normothermic global ischemia, Circulation, 64, 796, 10.1161/01.CIR.64.4.796 Port, 1983, Protection of the ischemic myocardium during cardiopulmonary bypass: Ca++ blockers vs hypothermia, Anesthesiology, 59, A42 Clark, 1981, The first American clinical trial of nifedipine in cardioplegia, J Thorac Cardiovasc Surg, 82, 848, 10.1016/S0022-5223(19)39234-7 Flameng, 1986, Nifedipine as an adjunct to St. Thomas' Hospital cardioplegia. A double-blind, placebo-controlled, randomized clinical trial, J Thorac Cardiovasc Surg, 91, 723, 10.1016/S0022-5223(19)35993-8 Christakis, 1986, Diltiazem cardioplegia. A balance of risk and benefit, J Thorac Cardiovasc Surg, 91, 647, 10.1016/S0022-5223(19)35984-7 Muntz, 1984, Redistribution of catecholamines in the ischemic zone of the dog heart, Am J Pathol, 114, 64 Corr, 1981, Increased α-adrenergic receptors in ischemic cat myocardium, J Clin Invest, 67, 1232, 10.1172/JCI110139 Sharma, 1983, Alpha-adrenergic-mediated accumulation of calcium in reperfused myocardium, J Clin Invest, 72, 802, 10.1172/JCI111051 Naylor, 1985, The protective effect of prazosin on the ischemic and reperfused myocardium, J Mol Cell Cardiol, 17, 685, 10.1016/S0022-2828(85)80068-7 Feinberg, 1982, Platelet deposition after surgically induced myocardial ischemia. An etiologic factor for reperfusion injury, J Thorac Cardiovasc Surg, 84, 815, 10.1016/S0022-5223(19)38929-9 Teoh, 1986, Prevention of myocardial platelet deposition and thromboxane release with dipyridamole, Circulation, 74, 145 Aherne, 1986, Prevention of ischemia-induced myocardial platelet deposition by exogenous prostacyclin, J Thorac Cardiovasc Surg, 92, 99, 10.1016/S0022-5223(19)35937-9 Huddleston, 1985, Amelioration of the deleterious effects of platelets activated during cardiopulmonary bypass. Comparison of a thromboxane synthetase inhibitor and a prostacyclin analogue, J Thorac Cardiovasc Surg, 89, 190, 10.1016/S0022-5223(19)38813-0 Addonizio, 1982, Mediation of cardiac ischemia by thromboxanes released from human platelets, Surgery, 92, 292 Schror, 1986, Prostacyclins are only weak antagonists of coronary vasospasm induced by authentic thromboxane A2 and serotonin, J Cardiovasc Pharmacol, 8, 607, 10.1097/00005344-198605000-00025 Aubry, 1985, Cardioprotective and antidysrhythmic effects of α1-adrenergic blockade during myocardial ischemia and reperfusion in the dog, J Cardiovasc Pharmacol, 7, s93, 10.1097/00005344-198500076-00016 Sheridan, 1980, Alpha-adrenergic contributions to dysrhythmia during myocardial ischemia and reperfusion in cats, J Clin Invest, 65, 161, 10.1172/JCI109647 Leysen, 1982, [3H] Ketanserin (R 41 468), a selective 3H-ligand for serotonin2-receptor binding sites, Mol Pharmacol, 21, 301 Janssen, 1985, Pharmacology of potent and selective S2-serotonergic antagonists, J Cardiovasc Pharmacol, 7, 2, 10.1097/00005344-198500077-00002 Rithter, 1986, Cardiovascular effects of ketanserin in the treatment of hypertension during coronary artery bypass surgery, J Cardiovasc Pharmacol, 8, 109, 10.1097/00005344-198601000-00017 Van der Starre, 1983, The use of ketanserin, a 5-hydroxytryptamine receptor antagonist, for treatment of postoperative hypertension following coronary artery bypass surgery, Anesth Analg, 62, 63, 10.1213/00000539-198301000-00011 Van Nueten, 1985, Serotonin and the blood vessel wall, J Cardiovasc Pharmacol, 7, s49, 10.1097/00005344-198500077-00015 Brazenor, 1982, Action of serotonin antagonists on dog coronary artery, Eur J Pharmacol, 81, 569, 10.1016/0014-2999(82)90346-6 De Clerck, 1982, Inhibition of 5-hydroxytryptamine-induced and amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist, Agents Actions, 12, 388, 10.1007/BF01965409 De, 1984, Plateletvessel wall interactions in hemostasis: Implication of 5hydroxytryptamine, Agents Actions, 15, 627, 10.1007/BF01966784 VanderWoude, 1983, Ketanserin provides improved myocardial protection, Surg Forum, 34, 307 1983, 330 Fleiss, 1981, Statistical Methods for Rates and Proportions, 64 Fleiss, 1981, Statistical Methods for Rates and Proportions, 65 Merchant, 1974, Sequential analysis of altered myocardial metabolism and contractility induced by normothermic arrest and reperfusion, J Surg Res, 16, 153, 10.1016/0022-4804(74)90023-7 Willerson, 1975, Reduced myocardial reflow and increased coronary vascular resistance following prolonged myocardial ischemia in the dog, Circ Res, 36, 771, 10.1161/01.RES.36.6.771 Schaper, 1979, Ultrastructural, functional, and biochemical criteria for estimation of reversibility of ischemic injury: A study on the effects of global ischemia on the isolated dog heart, J Mol Cell Cardiology, 11, 521, 10.1016/0022-2828(79)90428-0 Ketanserin, 1982, The First Pure and Selective 5-HT2 Receptor Blocking Agent, 25 Ketanserin, 1982, The First Pure and Selective 5-HT2 Receptor Blocking Agent, 26 Ketanserin, 1982, The First Pure and Selective 5-HT2 Receptor Blocking Agent, 39